Having trouble accessing articles? Reset your cache.

Merck acquiring Avalon lysosomal disorder play Calporta

Keen to take advantage of the rising importance of autophagy, Merck has acquired Avalon Ventures-backed Calporta for up to $576 million. Based on research from the University of Michigan, Calporta has preclinical compounds against TRPML1, a key ion channel in autophagy, to treat lysosomal storage and neurodegenerative disorders, including Alzheimer’s and Parkinson’s diseases.

Read the full word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE